热景生物涨2.03%，成交额1.68亿元，主力资金净流入1185.97万元

Core Viewpoint - The stock of Hotgen Biotech has shown a mixed performance in recent trading, with a year-to-date increase of 18.12% but a slight decline over the past five days, indicating potential volatility in investor sentiment [1]. Financial Performance - For the period from January to September 2025, Hotgen Biotech reported a revenue of 310 million yuan, representing a year-on-year decrease of 19.80% [2]. - The company experienced a net loss attributable to shareholders of 109 million yuan, which is a significant decline of 168.12% compared to the previous year [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 12.90% to 7,833, while the average number of circulating shares per person decreased by 11.43% to 11,835 shares [2]. - The stock price reached 191.36 yuan per share with a market capitalization of 17.741 billion yuan, and the trading volume was 168 million yuan, indicating active market participation [1]. Dividends and Institutional Holdings - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.344 million yuan paid out in the last three years [3]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Huatai-PineBridge Innovation Medicine Mixed Fund and an increase by ICBC Frontier Medical Stock A [3].